Jazz Pharmaceuticals (JAZZ) Non Operating Income (2011 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Non Operating Income of -$39.9 million for Q1 2026, up 25.7% year-over-year from -$31.7 million in Q1 2025, and up 12.13% quarter-over-quarter from -$45.4 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Non Operating Income (2011 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Non Operating Income history runs 16 years deep, the most recent figure standing at -$39.9 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 25.7% year-over-year to -$39.9 million; the TTM figure through Mar 2026 stood at -$181.2 million (up 19.69% YoY), while the FY2025 annual figure was -$195.1 million, up 18.08% from the prior year.
- Non Operating Income for Q1 2026 stood at -$39.9 million, up from -$45.4 million in the prior quarter.
- The five-year high for Non Operating Income was -$39.9 million in Q1 2026, with the low at -$80.2 million in Q3 2022.
- The 5-year median for Non Operating Income is -$63.2 million (2022), against an average of -$61.8 million.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income plunged 158.2% in 2022, then grew 27.11% in 2024.
- Jazz Pharmaceuticals' Non Operating Income stood at -$74.1 million in 2022, then grew by 5.13% to -$70.3 million in 2023, then advanced by 27.11% to -$51.3 million in 2024, then climbed by 11.41% to -$45.4 million in 2025, then rose by 12.13% to -$39.9 million in 2026.
- Business Quant data shows JAZZ's Non Operating Income at -$39.9 million in Q1 2026, -$45.4 million in Q4 2025, and -$48.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | -37.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.10 Mn |
| Mar 31, 2026 | -39.90 Mn |
| Dec 31, 2025 | -45.41 Mn |
| Sep 30, 2025 | -48.58 Mn |
| Jun 30, 2025 | -47.36 Mn |
| Mar 31, 2025 | -53.70 Mn |
| Dec 31, 2024 | -51.26 Mn |
| Sep 30, 2024 | -58.70 Mn |
| Jun 30, 2024 | -62.02 Mn |
| Mar 31, 2024 | -66.12 Mn |
| Dec 31, 2023 | -70.32 Mn |
| Sep 30, 2023 | -71.50 Mn |
| Jun 30, 2023 | -73.47 Mn |
| Mar 31, 2023 | -74.15 Mn |
| Dec 31, 2022 | -74.13 Mn |
| Sep 30, 2022 | -80.24 Mn |
| Jun 30, 2022 | -63.19 Mn |
| Mar 31, 2022 | -70.68 Mn |
| Dec 31, 2021 | -88.60 Mn |
| Sep 30, 2021 | -93.37 Mn |